Nauset Wealth Management’s Takeda Pharmaceutical TAK Stock Holding History

Nauset Wealth Management’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$0	Buy	+25	New	+$367	﹤0.01%	229

Other funds holding TAK

PPA

Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Nauset Wealth Management's TAK Position: Q1 2022 in Review

Nauset Wealth Management opened a new position in Takeda Pharmaceutical (TAK) in Q1 2022: 25 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #229 among its holdings.

288 funds tracked by Wall St. Rank hold TAK as of Q1 2022.

Nauset Wealth Management held 25 shares of Takeda Pharmaceutical worth $0 as of Q1 2022.
Takeda Pharmaceutical was a new Nauset Wealth Management position in Q1 2022.
Takeda Pharmaceutical made up ﹤0.01% of Nauset Wealth Management's portfolio in Q1 2022, its #229 holding.
288 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2022.

Based on Nauset Wealth Management's 13F filing for Q1 2022, filed 28 Apr 2022.